Could alterations in maternal plasma visfatin concentration participate in the phenotype definition of preeclampsia and SGA?

Simple item page
dc.contributor.authorMazaki Tovi, Shali
dc.contributor.authorRomero, Roberto
dc.contributor.authorKim, Sun Kwon
dc.contributor.authorVaisbuch, Edi
dc.contributor.authorKusanovic, Juan Pedro
dc.contributor.authorErez, Offer
dc.contributor.authorChaiworapongsa, Tinnakorn
dc.contributor.authorGotsch, Francesca
dc.contributor.authorMittal, Pooja
dc.contributor.authorNhan Chang, Chia Ling
dc.contributor.authorThan, Nandor Gabor
dc.contributor.authorGomez, Ricardo
dc.contributor.authorNien, Jyh Kae
dc.contributor.authorEdwin, Samuel S.
dc.contributor.authorPacora, Percy
dc.contributor.authorYeo, Lami
dc.contributor.authorHassan, Sonia S.
dc.date.accessioned2024-01-10T13:47:12Z
dc.date.available2024-01-10T13:47:12Z
dc.date.issued2010
dc.description.abstractObjective. Women with preeclampsia and those who delivered a small-for-gestational-age (SGA) neonate share several mechanisms of disease, including chronic uteroplacental ischemia and failure of physiologic transformation of the spiral arteries. However, the clinical manifestation of these obstetrical syndromes is remarkably different. It has been proposed that an altered maternal metabolic state, as well as a unique circulating cytokines milieu, predispose women to develop either preeclampsia or SGA. Compelling evidence suggests that adipose tissue orchestrates both metabolic pathways and immunological responses via the production of adipokines. Visfatin is a novel adipocytokine with metabolic and immunomodulating properties. The objective of this study was to determine whether preeclampsia and SGA are associated with alterations in maternal circulating visfatin concentrations.
dc.description.abstractMethods. This cross-sectional study included pregnant women in the following groups: (1) normal pregnancy (n = 158); (2) patients with preeclampsia (n = 43) of which 32 had an AGA and 11 had an SGA neonate; (3) patients without preeclampsia who delivered an SGA neonate (n = 55). Maternal plasma visfatin concentrations were measured by ELISA. Nonparametric tests and multiple linear regression analysis were used.
dc.description.abstractResults. (1) Women who delivered an SGA neonate had a higher median maternal plasma visfatin concentration than those with a normal pregnancy (20.0 ng/ml, interquartile range: 17.2-24.6 vs. 15.2 ng/ml, 12.1-19.2, respectively; P < 0.001) and than those with preeclampsia (14.5 ng/ml, 12.5-18.7; P < 0.001); (2) the median maternal plasma visfatin concentration did not differ significantly between patients with preeclampsia and those with a normal pregnancy (P = 0.8); (3) among patients with preeclampsia, there was no significant difference in the median maternal plasma visfatin concentration between those with or without an SGA neonate (P = 0.5); (4) in a linear regression model, delivery of an SGA neonate and pregestational body mass index were independently associated with increased visfatin concentration after adjustment for confounding factors (maternal age, smoking, gestational age at blood collection and the presence of preeclampsia or SGA).
dc.description.abstractConclusion. (1) Patients with SGA, but not those with preeclampsia, had a higher maternal plasma visfatin concentration than those with a normal pregnancy; (2) this finding suggests differential involvement of visfatin in SGA and preeclampsia; (3) we propose that changes in circulating maternal visfatin concentration may be implicated in the phenotypic definitions and distinction of preeclampsia and SGA.
dc.description.funderPerinatology Research Branch, Division of Intramural Research Program of the Eunice Kennedy Shriver National Institute of Child Health and Human Development, NIH, DHHS
dc.description.funderEUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT
dc.description.funderEUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT
dc.fechaingreso.objetodigital2024-05-23
dc.format.extent12 páginas
dc.fuente.origenWOS
dc.identifier.doi10.3109/14767050903301017
dc.identifier.eissn1476-4954
dc.identifier.issn1476-7058
dc.identifier.pubmedidMEDLINE:19900033
dc.identifier.urihttps://doi.org/10.3109/14767050903301017
dc.identifier.urihttps://repositorio.uc.cl/handle/11534/79246
dc.identifier.wosidWOS:000280592200015
dc.information.autorucMedicina;Gómez R;S/I;80926
dc.information.autorucMedicina;Nien JK;S/I;2778
dc.issue.numero8
dc.language.isoen
dc.nota.accesocontenido parcial
dc.pagina.final868
dc.pagina.inicio857
dc.publisherTAYLOR & FRANCIS LTD
dc.revistaJOURNAL OF MATERNAL-FETAL & NEONATAL MEDICINE
dc.rightsacceso restringido
dc.subjectAdipokine
dc.subjectpregnancy
dc.subjectfetal growth
dc.subjectmetabolism
dc.subjectobesity
dc.subjectCOLONY-ENHANCING FACTOR
dc.subjectFOR-GESTATIONAL-AGE
dc.subjectPLACENTAL GROWTH-FACTOR
dc.subjectFACTOR RECEPTOR-1 CONCENTRATION
dc.subjectCIRCULATING ANGIOGENIC FACTORS
dc.subjectFETAL MEMBRANE DISTENSION
dc.subjectUTERINE ARTERY DOPPLER
dc.subjectNECROSIS-FACTOR-ALPHA
dc.subjectNORMAL-PREGNANCY
dc.subjectINSULIN-RESISTANCE
dc.subject.ods05 Gender Equality
dc.subject.ods03 Good Health and Well-being
dc.subject.odspa05 Igualdad de género
dc.subject.odspa03 Salud y bienestar
dc.titleCould alterations in maternal plasma visfatin concentration participate in the phenotype definition of preeclampsia and SGA?
dc.typeartículo
dc.volumen23
sipa.codpersvinculados80926
sipa.codpersvinculados2778
sipa.indexWOS
sipa.indexScopus
sipa.trazabilidadCarga SIPA;09-01-2024
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
2024-05-23. Could alterations in maternal plasma visfatin concentration participate in the phenotype definition of preeclampsia and SGA - .pdf
Size:
3.69 KB
Format:
Adobe Portable Document Format
Description:
Download
Collections
Artículos de revistas